What is Marinus Pharmaceuticals?
Marinus Pharmaceuticals is a clinical-stage biopharmaceutical enterprise dedicated to the development of ganaxolone. The company's core mission centers on leveraging a unique mechanism of action to provide efficacious and safe treatment options for patients suffering from rare forms of epilepsy, such as CDD, as well as postpartum depression and refractory status epilepticus. By targeting well-characterized brain pathways, the firm aims to deliver anti-seizure, anti-depressant, and anti-anxiety benefits. Its market position is defined by a commitment to precision medicine and the development of versatile delivery systems that maximize therapeutic utility across adult and pediatric demographics.
How much funding has Marinus Pharmaceuticals raised?
Marinus Pharmaceuticals has raised a total of $360.2M across 11 funding rounds:
Series C
$21M
Stock Offering
$41.3M
Stock Offering
$27.7M
Stock Offering
$40.3M
Stock Offering
$45M
Stock Offering
$70M
Other Financing Round
$30M
Other Financing Round
$32.5M
Series C (2013): $21M featuring Domain Associates, Foundation Medicine, Canaan Partners, RusnanoMedInvest, and Sofinnova Ventures
Stock Issuance/Offering (2014): $41.3M backed by Undisclosed
Stock Issuance/Offering (2015): $27.7M with participation from Undisclosed
Stock Issuance/Offering (2017): $40.3M led by Bain Capital
Stock Issuance/Offering (2018): $45M supported by Undisclosed
Stock Issuance/Offering (2019): $70M featuring Undisclosed
Other Financing Round (2022): $30M backed by Oaktree
Other Financing Round (2022): $32.5M with participation from H.C. Wainwright & Co. and Morgan Stanley
Key Investors in Marinus Pharmaceuticals
Domain Associates
An investment advisory firm established in 1985, specializing in biotech investments with a track record of supporting 194 biopharmaceutical companies.
Canaan Partners
An early-stage venture capital firm that invests in technology and healthcare, backing founders from seed through growth stages in biopharma and digital health.
Sofinnova Ventures
A leading European venture capital firm in life sciences that acts as a hands-on company builder across the entire value chain of biotech investments.
What's next for Marinus Pharmaceuticals?
Looking ahead, the strategic deployment of the $32.5M will likely focus on the completion of ongoing pivotal clinical trials and the potential commercialization of its lead assets. As the company transitions from intensive research and development toward regulatory milestones, the focus will shift to scaling operational capabilities and strengthening its market presence. The continued support from long-term institutional partners suggests a stable outlook for the company as it seeks to bring transformative neuropsychiatric therapies to global markets, ultimately aiming to improve patient outcomes in high-need therapeutic areas.
See full Marinus Pharmaceuticals company page
